摘要
乙型肝炎病毒相关性肾炎(HBV-GN)是临床常见的继发性肾脏病,它的治疗尚无明确、统一的原则可循。目前国内外对现有的治疗HBV-GN药物的疗效,进行了多个大规模随机、对照的临床研究并对其进行相关系统评价及Mate分析,以期对HBV-GN的治疗选择更合适的治疗药物,减少治疗上的盲目性,提高治疗HBV的临床疗效,延缓HBV-GN进展到终末期肾衰竭的进程。本文以国内外研究文献为基础,对文献资料进行分析、归纳和总结,综述乙肝相关性肾炎治疗的研究现状。现已有多种药物被用于治疗乙肝相关性肾炎,但迄今为止最佳的治疗方案尚无定论。综合现有研究发现由于单独使用一种抗病毒药物或免疫抑制剂治疗效果有限且易复发,因此联合或序贯使用两种或两种以上药物,抑制病毒更快,耐药发生较少,肾脏损伤进展较慢,临床结局较好。
Hepatitis B virus associated glomerulonephritis （HBV-GN） is a common clinical secondary renal disease, its treatment is not clear, unified principles to follow. At home and abroad on the efficacy of drug treatment of HBV-GN were multiple large randomized, controlled clinical studies and relevant systematic reviews and Mate to more appropriate treatment of the treatment options for HBV-GN drugs to reduce blindness treatment to improve the clinical efficacy of the treatment of HBV, delaying the process of I-IBV-GN progress to end-stage renal failure. In this paper, based on domestic and international research literature, literature analysis and summarized the research status of the review of hepatitis B associated glomemlonephritis treatment. Now there are a variety of drugs for the treatment of hepatitis B associated glomerulonephritis, but by far the best course of treatment is inconclusive. Synthesis of existing research found an antiviral effect or immunosuppressive therapy used alone and easy to relapse, joint or sequential use of two or more drugs to suppress the virus faster, less resistance occurs, the kidneys the injury slow progress, better clinical outcomes.
出处
《现代生物医学进展》
CAS
2013年第11期2182-2184,2145,共4页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(81150032)
关键词
乙肝相关性肾炎
治疗
系统评价
Mate分析
Hepatitis B virus-associated glomerulonephritis
Treatment
System evaluation
Mate analysis
